title: Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a single integrated health network.
abstract: OBJECTIVE
  To determine the association between the discontinuation of clopidogrel therapy prior to 1 year and the risk of acute myocardial infarction (AMI) hospitalization, coronary intervention or all-cause mortality in a cohort of managed-care patients following AMI hospitalization or stent insertion.
  
  
  METHODS
  This observational cohort study included 1152 patients enrolled in the Health Alliance Plan who were hospitalized for AMI, or who underwent coronary stent placement. Clopidogrel use was assessed using pharmacy claims data. The association between discontinuation of clopidogrel prior to 1 year following the initial ACS event and the primary outcome of AMI hospitalization/procedure was assessed using Cox proportional hazards models. Additionally, an analysis was conducted to determine the association of discontinuation prior to 1 year with a secondary composite outcome of AMI hospitalization/coronary stent procedure or all-cause mortality.
  
  
  METHODS
  The primary outcome was AMI hospitalization or procedure. The secondary outcome was a composite of AMI hospitalization/ procedure, or all-cause mortality.
  
  
  RESULTS
  Discontinuation of clopidogrel in the total cohort of patients was associated with a significantly higher risk of the primary outcome of AMI hospitalization/ coronary intervention (HR 2.712, 95% CI 1.634-4.502). Consistent with this finding, discontinuation of clopidogrel was also associated with a significantly higher risk of the secondary composite endpoint (HR 1.844, 95% CI 1.281-2.653).
  
  
  CONCLUSIONS
  In patients enrolled in an integrated health network, clopidogrel discontinuation prior to 1 year following AMI hospitalization or stent placement is associated with adverse outcomes including greater risk of death, AMI hospitalization or coronary intervention. These results should be interpreted within the context and limitations of observational research, which cannot attribute causality.
authors.affiliation: Analytica International, New York, NY, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Wiederkehr
authors.forename: Karina
authors.initials: K
authors.lastname: Berenson
authors.forename: Roman
authors.initials: R
authors.lastname: Casciano
authors.forename: Lee
authors.initials: L
authors.lastname: Stern
authors.forename: Dinara
authors.initials: D
authors.lastname: Makenbaeva
authors.forename: Essy
authors.initials: E
authors.lastname: Mozaffari
authors.forename: Lois
authors.initials: L
authors.lastname: Lamerato
authors.forename: John
authors.initials: J
authors.lastname: Corbelli
mesh_terms: D000368:Aged; D000465:Algorithms; D013504:Cardiovascular Surgical Procedures / Q000706:statistics & numerical data; D000077144:Clopidogrel; D015331:Cohort Studies; D003327:Coronary Disease / Q000209:etiology / Q000401:mortality / Q000601:surgery*; D019033:Delivery of Health Care, Integrated; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors; D015607:Stents; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D028761:Withholding Treatment / Q000706:statistics & numerical data
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine